Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20836890 | 0.93 | HDAC11 (0.57) | HDAC11 | |
| SCHEMBL29624696 | 0.93 | HDAC11 (0.57) | HDAC11 | |
| SCHEMBL20096556 | 0.93 | HDAC11 (0.57) | HDAC11 | |
| SCHEMBL20096553 | 0.93 | HDAC11 (0.57) | HDAC11 | |
| SCHEMBL29624687 | 0.93 | HDAC11 (0.57) | HDAC11 | |
| SCHEMBL20096675 | 0.91 | HDAC11 (0.58) | HDAC11HDAC6NR1H2 | |
| SCHEMBL20132806 | 0.87 | HDAC11 (0.62) | HDAC11HDAC6 | |
| SCHEMBL20132808 | 0.86 | HDAC11 (0.64) | HDAC11HDAC6 | |
| SCHEMBL20096998 | 0.84 | HDAC11 (0.64) | HDAC11CTSBCTSSCTSK | |
| SCHEMBL20132854 | 0.82 | HDAC11 (0.73) | HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885NR1H2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.